5 recruiting, 2 active not recruiting, 2 completed, 2 terminated. 5 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Suspended 1, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Osteosarcoma in Children: new trials by email Literature Review of Osteosarcoma in Children trials Research Report on Osteosarcoma in Children
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles - Osteosarcoma, Pediatric Osteosarcoma | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 530 | 2026-10-07 | 2026-10-26 |
| The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma High-dose Methotrexate - Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults | Phase 2 | Recruiting | Wake Forest University Health Sciences | 46 | 2026-09-01 | 2026-10-13 |
| Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma Tegavivint, Gemcitabine - Osteosarcoma Recurrent, Osteosarcoma in Children | Phase 1 | Recruiting | Emory University | 24 | 2026-01-22 | 2026-10-19 |
| A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma OMO-103 - Osteosarcoma, Osteosarcoma in Children | Phase 2 | Recruiting | Vall d'Hebron Institute of Oncology | 10 | 2024-12-27 | 2025-01-10 |
| Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma Cabozantinib, Best Supportive Care (BSC) - Osteosarcoma, Osteosarcoma in Children | Phase 2 | Terminated | Ipsen | 10 | 2024-11-22 | 2026-03-31 |
| Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors KLF factor (4 and 7) - Osteosarcoma in Children, Ewing Sarcoma of Bone or Soft Tissue | Recruiting | Ain Shams University | 30 | 2024-08-16 | 2025-04-20 | |
| Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma Dinutuximab beta - Osteosarcoma in Children | Phase 2 | Suspended | Prof. Franca Fagioli | 22 | 2023-11-30 | 2023-11-18 |
| Long-term Evaluation of the Quality of Life of Former Patients Treated With Orthopedic Surgery, With or Without Radiotherapy Quality of life questionnaire - Osteosarcoma in Children | Completed | Institut Cancerologie de l'Ouest | 300 | 2022-11-18 | 2023-08-02 | |
| SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma Regorafenib 40 MG, Regorafenib 20MG, Nivolumab - Osteosarcoma, Osteosarcoma in Children | Phase 2 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 48 | 2021-06-04 | 2025-10-31 |
| Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas Osteosarcoma in Children | Unknown | University Hospital, Strasbourg, France | 30 | 2020-02-01 | 2021-11-04 | |
| Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Nivolumab, Azacitidine, Post Treatment Surgery - Osteosarcoma, Osteosarcoma in Children | Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 21 | 2019-10-03 | 2026-07-30 |
| Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity GRID radiotherapy - Osteosarcoma in Children, Radiation Toxicity | Not applicable | Terminated | University of Arkansas | 1 | 2017-07-25 | 2022-07-20 |
| 3D Printed Personalized Extendable Prosthesis 3D printed personalized extendable prosthesis - Osteosarcoma in Children | Completed | Yuxi Su | 25 | 2015-10-01 | 2023-04-03 |
Osteosarcoma (9) · Bone Neoplasms (1) · Hypoxia (1) · Necrosis (1) · Neoplasm Metastasis (1) · Radiation Injuries (1) · Sarcoma (1) · Sarcoma, Ewing (1)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Bone Tissue (9) · Neoplasms, Connective Tissue (9) · Neoplasms, Connective and Soft Tissue (9) · Sarcoma (8) · Bone Diseases (1) · Musculoskeletal Diseases (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Signs and Symptoms, Respiratory (1) · Wounds and Injuries (1)
Nivolumab (2) · Azacitidine (1) · Gemcitabine (1) · MAX protein, human (1) · Methotrexate (1) · Standard of Care (1) · cabozantinib (1) · dinutuximab (1) · regorafenib (1)
Ain Shams University (1) · Emory University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institut Cancerologie de l'Ouest (1) · Ipsen (1) · Prof. Franca Fagioli (1) · Sarcoma Alliance for Research through Collaboration (1) · University Hospital, Strasbourg, France (1) · University of Arkansas (1) · Vall d'Hebron Institute of Oncology (1) · Wake Forest University Health Sciences (1) · Yuxi Su (1)
United States (6) · France (4) · Italy (3) · Spain (3) · Netherlands (2) · Poland (2) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · Egypt (1) · Finland (1) · Germany (1) · Sweden (1) · United Kingdom (1)
Fatma S E Ebeid (1) · Franca Fagioli, MD (1) · Leslie Harrell, MD (1) · Mihaela M Druta, MD (1) · Patrick A. Thompson, MD (1) · Thomas Cash, MD, MSc (1) · Thomas Russell, MD (1) · Yuxi Su (1)
2023 (2)